Evidence map›Paper›PMID 33165532›Full record

ArticleBioinformatics (Oxford, England)2021

MEScan: a powerful statistical framework for genome-scale mutual exclusivity analysis of cancer mutations.

Sisheng Liu, Jinpeng Liu, Yanqi Xie, Tingting Zhai, Eugene W Hinderer, Arnold J Stromberg, Nathan L Vanderford, Jill M Kolesar, Hunter N B Moseley, Li Chen and 2 more

Open access · greenAbstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Sisheng LiuAdcolony Inc., Bellevue, WA 98004, USA.
Jinpeng LiuMarkey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.
Yanqi XieMolecular and Cellular Biochemistry, University of Kentucky, Lexington, KY 40536, USA.
Tingting ZhaiDepartment of Statistics, University of Kentucky, Lexington, KY 40536, USA.
Eugene W HindererMolecular and Cellular Biochemistry, University of Kentucky, Lexington, KY 40536, USA.
Arnold J StrombergDepartment of Statistics, University of Kentucky, Lexington, KY 40536, USA.
Nathan L VanderfordMarkey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.
Jill M KolesarMarkey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.
Hunter N B MoseleyMarkey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.ORCID 0000-0003-3995-5368
Li ChenMarkey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.
Chunming LiuMarkey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.
Chi WangMarkey Cancer Center, University of Kentucky, Lexington, KY 40536, USA.ORCID 0000-0001-8984-4995
University of Kentucky · USBellevue Hospital Center · US

Funding

WKU Lead Faculty AwardP20GM103436 · NIGMS · UNIVERSITY OF LOUISVILLE · PI ERIC C ROUCHKA · 2012 to 2026
$60.1M
University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Bernard Mark Evers · 2013 to 2026
$38.3M
Kentucky Center for Clinical and Translational ScienceUL1TR001998 · NCATS · UNIVERSITY OF KENTUCKY · PI HARTMANN, KATHERINE E, KERN, PHILIP A · 2016 to 2025
$34.2M
Statistical Detection and Biochemical Classification of Cancer Driver Mutation Patterns in Biological NetworksR21CA205778 · NCI · UNIVERSITY OF KENTUCKY · PI MOSELEY, HUNTER NATHANIEL, WANG, CHI · 2016 to 2017
$382k
NCATS NIH HHS UL1 TR001998NCI NIH HHS P30 CA177558NCI NIH HHS R21 CA205778NIGMS NIH HHS P20 GM103436
6 · The paper itself

Abstract

motivationCancer somatic driver mutations associated with genes within a pathway often show a mutually exclusive pattern across a cohort of patients. This mutually exclusive mutational signal has been frequently used to distinguish driver from passenger mutations and to investigate relationships among driver mutations. Current methods for de novo discovery of mutually exclusive mutational patterns are limited because the heterogeneity in background mutation rate can confound mutational patterns, and the presence of highly mutated genes can lead to spurious patterns. In addition, most methods only focus on a limited number of pre-selected genes and are unable to perform genome-wide analysis due to computational inefficiency.

resultsWe introduce a statistical framework, MEScan, for accurate and efficient mutual exclusivity analysis at the genomic scale. Our framework contains a fast and powerful statistical test for mutual exclusivity with adjustment of the background mutation rate and impact of highly mutated genes, and a multi-step procedure for genome-wide screening with the control of false discovery rate. We demonstrate that MEScan more accurately identifies mutually exclusive gene sets than existing methods and is at least two orders of magnitude faster than most methods. By applying MEScan to data from four different cancer types and pan-cancer, we have identified several biologically meaningful mutually exclusive gene sets. AVAILABILITY AND IMPLEMENTATION: MEScan is available as an R package at https://github.com/MarkeyBBSRF/MEScan. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.

Indexed as

Computational BiologyNeoplasmsAlgorithmsGenomicsHumansMutation

Identifiers

PMID33165532
PMCPMC8189684
OpenAlexW3100884242

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.